Financial Performance - Revenue increased by RMB 1,292.1 million or 16.5% to RMB 9,108.0 million[2] - Gross profit rose by RMB 1,186.8 million or 17.9% to RMB 7,828.4 million, with a gross margin of 86.0%[2] - Net profit attributable to equity holders increased by RMB 541.1 million or 34.9% to RMB 2,090.3 million[2] - Adjusted operating profit increased by RMB 366.4 million or 18.8% to RMB 2,318.8 million[2] - EBITDA rose by RMB 784.7 million or 32.8% to RMB 3,173.8 million[2] - Adjusted operating EBITDA increased by RMB 633.9 million or 22.9% to RMB 3,402.3 million[2] - Total comprehensive income for the year was RMB 2,217.5 million, compared to RMB 1,586.3 million in the previous year[4] - The company reported a net profit of RMB 2,217,549, an increase from RMB 1,586,292 in the previous year, representing a growth of approximately 39.8%[5] - Total comprehensive income for the year reached RMB 2,285,205, compared to RMB 1,484,965 in the prior year, indicating a year-over-year increase of about 53.8%[5] Assets and Liabilities - Non-current assets totaled RMB 14,865,806, up from RMB 14,432,345 in the previous year, reflecting an increase of approximately 3%[7] - Current assets increased to RMB 9,346,934 from RMB 9,192,683, marking a growth of about 1.7%[7] - The company's cash and cash equivalents stood at RMB 2,142,651, a decrease from RMB 2,611,161, indicating a decline of approximately 17.9%[7] - Trade receivables rose to RMB 1,305,160, compared to RMB 1,095,132 in the previous year, showing an increase of about 19.2%[7] - Current liabilities increased to RMB 5,463,524 from RMB 3,727,610, representing a significant rise of approximately 46.6%[7] - Non-current liabilities decreased from RMB 3,383,818 thousand in 2023 to RMB 712,886 thousand in 2024, a reduction of approximately 78.9%[8] - The net asset value increased from RMB 16,513,600 thousand in 2023 to RMB 18,036,330 thousand in 2024, representing a growth of about 9.2%[8] - The equity attributable to owners of the parent rose from RMB 14,033,771 thousand in 2023 to RMB 15,436,258 thousand in 2024, an increase of approximately 10%[8] Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.25 per share for the year ended December 31, 2024[2] - The group plans to distribute a final dividend of HKD 0.25 per share for the year ended December 31, 2023, amounting to RMB 545,302 thousand[38] Market and Product Development - The company plans to expand its market presence and invest in new product development to drive future growth[5] - The company introduced new products including Semaglutide injection and Paclitaxel oral solution in 2024, expanding its therapeutic areas[50] - The company maintained a market share of 66.6% in the platelet reduction treatment market in China for its core product, Tevaziv[50] - The company captured 42.0% of the total market share in the rhEPO market in China in 2024[50] Research and Development - The group has a robust R&D platform covering various innovative large and small molecule products, with a focus on antibody discovery and clinical trial management[76] - The group is advancing multiple innovative biopharmaceuticals and small molecule drugs, including SSS06 (NuPIAO) for anemia and CS1003 for advanced liver cancer[77] - The company completed the Phase III clinical trial for NuPIAO (SSS06) for treating anemia in chronic kidney disease patients in January 2024, achieving the primary endpoint[84] Financial Management - The total tax expense for the year was RMB 500,536 thousand, up from RMB 392,167 thousand in 2023, indicating an increase of approximately 27.7%[35] - The effective tax rate for the group for the year ended December 31, 2024, was 18.4%, down from 19.8% in 2023[36] - Total financing costs decreased to RMB 190,846 thousand in 2024 from RMB 212,296 thousand in 2023, reflecting a reduction of about 10.1%[30] Corporate Governance - The group is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[135] - The audit committee, consisting of three independent non-executive directors, has reviewed and approved the accounting principles and practices adopted by the group for the reporting period[140] Employee and Operational Costs - Employee benefits expenses totaled RMB 1,564,714 thousand in 2024, compared to RMB 1,362,262 thousand in 2023, marking an increase of about 14.8%[29] - Employee costs, including directors' remuneration (excluding any retirement benefit plan contributions), amounted to approximately RMB 1,469.8 million during the reporting period, compared to approximately RMB 1,271.5 million in the same period last year[131] Compliance and Reporting - The financial statements are prepared in accordance with International Financial Reporting Standards, ensuring compliance and transparency[10] - Ernst & Young has confirmed that the financial information in the preliminary results announcement is consistent with the group's consolidated financial statements[141]
三生制药(01530) - 2024 - 年度业绩